PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDXBusiness Wire • 04/21/23
Merck's $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunologyMarket Watch • 04/17/23
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations LoomInvestors Business Daily • 04/17/23
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following CAccesswire • 04/16/23
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract CancerBusiness Wire • 04/16/23
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.Business Wire • 04/16/23
FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaBusiness Wire • 04/13/23
Merck's stock leads the Dow's early gainers after Citi turns bullish, raises price target by 24%Market Watch • 04/13/23
Merck shares fall after US FDA halts new patient enrollment of MS drug candidate trialsProactive Investors • 04/12/23
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - Cardinal Health (NYSE:CAH), Amgen (NASDAQ:AMGN)Benzinga • 04/12/23